Stockscreener 앱 받기
0.47
8.33%
-0.0427
전일 마감가:
$0.5127
열려 있는:
$0.5146
하루 거래량:
88,010
Relative Volume:
0.58
시가총액:
$2.10M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-6.00%
1개월 성능:
-37.33%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$0.46
$0.5146
1주일 범위
$0.4111
$0.5147
52주 변동 폭
$0.4111
$1.04
Naya Biosciences Stock (NAYA) Company Profile
명칭
Naya Biosciences
전화
(978) 878-9505
주소
5582 BROADCAST COURT, SARASOTA
NAYA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NAYA
Naya Biosciences
|
0.47 | 2.10M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
116.79 | 201.01B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
395.85 | 150.90B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
100.91 | 148.72B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
88.38 | 113.33B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
69.97 | 41.27B | 6.60B | 4.16B | 490.10M | 6.93 |
Naya Biosciences 주식(NAYA)의 최신 뉴스
NAYA Biosciences Raises $9.5M Amid Nasdaq Compliance Issues - TipRanks
NAYA Biosciences sets public offering at $0.70 per unit By Investing.com - Investing.com South Africa
Lakewood Ranch life sciences firm seeks to raise $9.5M through public offering - Business Observer
NAYA Stock Hits 52-Week Low at $0.62 Amid Market Challenges - Investing.com
NAYA Biosciences Announces Pricing of $9.5 Million Public Offering - GlobeNewswire
NAYA Biosciences sets public offering at $0.70 per unit - Investing.com
NAYA Biosciences Raises $9.5M in Public Offering to Fund Acquisition and Growth Plans - StockTitan
Pre-market Movers: CDT, NARI, GDTC, NARI... - RTTNews
NAYA Biosciences expands oncology pipeline with new antibody By Investing.com - Investing.com Nigeria
NAYA Biosciences expands oncology pipeline with new antibody - Investing.com
NAYA Biosciences Announces Development of NY-500, a Novel AI-Optimized PD-1 x VEGF Bifunctional Antibody - GlobeNewswire
NAYA Biosciences Unveils NY-500, AI-Enhanced Cancer Antibody Outperforming Keytruda - StockTitan
NAYA (NAYA Biosciences) Long-Term Debt & Capital Lease Obli - GuruFocus.com
The horror of Saydnaya jail, symbol of Assad excesses - News- Graphic
INVO Bioscience : Expands its Presence in Eurasia with New Distribution Agreements to Commercialize the INVOcell In Vivo Fertilization System - Marketscreener.com
Grapevine December 15, 2024: Changing of the guard - The Jerusalem Post
NAYA Biosciences Inc. (NAYA) reports earnings - Quartz
NAYA (NAYA Biosciences) Profitability Rank : 2 (As of Jun. 2024) - GuruFocus.com
Pre-market Movers: ELAB, PHGE, CLDI, BJDX... - RTTNews
NAYA Biosciences to Present Translational Insights to - GlobeNewswire
NAYA Biosciences to Present Translational Insights to Support Phase I/IIa Clinical Trials for its GPC3-Targeting NK Engager Bispecific Antibody at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - GlobeNewswire
INVO Bioscience, Inc. announced that it has received $0.275 million in funding - Marketscreener.com
INVO Bioscience Closes Wisconsin Fertility Institute Acquisition - Marketscreener.com
INVO Bioscience Closes Exclusive U.S. Licensing Agreement with Ferring Pharmaceuticals to Commercialize the Novel Invocell System for Use in the Treatment of Infertility - Marketscreener.com
INVO Bioscience, Inc. Announces Appointment of Pressly Ahammed as Director of International Business Development - Marketscreener.com
INVOcell Appoints Yve Lyppens as Director Business Development Asia Pacific - Marketscreener.com
INVO Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 - Marketscreener.com
INVO Bioscience, Inc. Announces Grand Opening of "Positib Fertility, an INVO Center" in Monterrey, Mexico on November 1, 2021 - Marketscreener.com
INVO Bioscience Announces the Appointment of Steve Shum as Chief Executive Officer - Marketscreener.com
NAYA Biosciences Announces Initiation of Phase 1/2a - GlobeNewswire
NAYA (NAYA Biosciences) Enterprise Value : $15.50 Mil (As of Oct. 25, 2024) - GuruFocus.com
Top Premarket Gainers - Marketscreener.com
NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular Carcinoma - The Manila Times
The court declared bankruptcy of MPG AgroProduction OÜ - The Manila Times
INVO Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 - Marketscreener.com
INVO Bioscience, Inc. announced that it expects to receive $0.5 million in funding from FirstFire Capital Management LLC - Marketscreener.com
INVO Bioscience changes name, trading symbol after merger - Business Observer
INVO Bioscience confirms name change, new trading symbol following NAYA merger - TipRanks
INVO Bioscience Confirms Corporate Name Change and New Trading Symbol in Connection with Its Recent Merger with NAYA Biosciences - The Manila Times
CERo Therapeutics, Inc. Provides Corporate Update - The Manila Times
INVO Bioscience (NASDAQ: INVO) Stock Sees Bullish Momentum on Merger News - DRP Journal
INVO Bioscience Completes Merger with NAYA Biosciences - TipRanks
Sarasota fertility company completes merger with bioscience firm - Business Observer
INVO Bioscience merges with NAYA, eyes oncology market - Investing.com
INVO Bioscience and NAYA Biosciences Close Merger, Combined Company to Operate as NAYA Biosciences (NASDAQ: NAYA) - The Manila Times
Sify Technologies announces the appointment of Ms. Padmaja Chunduru as Director on the Board - The Manila Times
INVO Bioscience, NAYA Biosciences close merger - TipRanks
INVO Bioscience secures $265,000 through Merchant Cash Advance - Investing.com India
INVO Bioscience faces Nasdaq delisting over share price - Investing.com
INVO Bioscience extends merger agreement with NAYA - Investing.com
INVO Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
Naya Biosciences (NAYA) 재무 분석
Naya Biosciences (NAYA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
3.55%
자본화:
|
볼륨(24시간):